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Abstract 18 
Covalent modification of protein by drugs may disrupt self-tolerance leading to lymphocyte 19 
activation. Determination of the threshold required for this process has not hitherto been 20 
possible. We have therefore performed quantitative mass spectrometric analyses to define the 21 
epitopes formed in tolerant and hypersensitive patients taking the β-lactam antibiotic 22 
piperacillin and the threshold required for T-cell activation. A hydrolysed piperacillin hapten 23 
was detected on 4 Lys residues of HSA isolated from tolerant patients. The level of modified 24 
Lys541 ranged from 2.6-4.8%. Analysis of plasma from hypersensitive patients revealed the 25 
same pattern and levels of modification 1-10 days after commencement of therapy. 26 
Piperacillin-responsive skin-homing CD4+ clones expressing an array of Vβ receptors were 27 
activated in a dose, time and processing-dependent manner; analysis of incubation medium 28 
revealed that 2.6% of Lys541 in HSA was modified when T-cells were activated. 29 
Piperacillin-HSA conjugates that had levels and epitopes identical to those detected in 30 
patients were shown to selectively stimulate additional CD4+ clones, which expressed a more 31 
restricted Vβ repertoire. To conclude, the levels of piperacillin-HSA modification that 32 
activated T-cells are equivalent to the ones formed in hypersensitive and tolerant patients, 33 
which indicates that threshold levels of drug antigen are formed in all patients. Thus, the 34 
propensity to develop hypersensitivity is dependent on other factors such as on the presence 35 
of T-cells within an individual’s repertoire that can be activated with the β-lactam hapten 36 
and/or an imbalance in immune regulation. 37 
 38 
 39 
 40 
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Introduction 42 
Human exposure to drug haptens results in a high prevalence of T-cell-mediated reactions 43 
often referred to as drug hypersensitivity (1). It has been postulated that covalent binding of 44 
the hapten to protein and the formation of neoantigens represents a crucial initiating event in 45 
the iatrogenic disease (2); however, there is a need to develop sensitive methods to determine 46 
the quantity of drug protein adducts formed in patients and to explore whether such adducts 47 
act as antigens to activate patient T-cells. 48 
 49 
β-lactam antibiotics are the most common cause of drug hypersensitivity. They form adducts 50 
with protein through an irreversible covalent bond and as such represent an ideal drug class to 51 
investigate the relationship between hapten protein binding and induction of an immune 52 
response. For adduct formation, the β-lactam ring is targeted by reactive lysine residues in 53 
protein (3). Through evolution of bioanalytical technologies, mainly protein mass 54 
spectrometry, it has been possible to probe the nature of the drug protein interaction in greater 55 
detail. β-lactam antibiotics bind to extracellular protein, in particular human serum albumin 56 
(HSA),
2
 with a degree of selectivity (4-9). Adduct formation on HSA is time- and 57 
concentration-dependent and modifications are detected at fewer than 10% of available 58 
nucleophilic lysine residues. The selective binding interaction does not only relate to pKa and 59 
therefore reactivity of the side-chain amino group as most adducts form at or around Sudlow 60 
sites, which are hydrophobic pockets involved in the non-covalent binding of drugs and 61 
endogenous molecules (10,11).  62 
 63 
Preliminary studies indicated that T-cells from patients with hypersensitivity can be activated 64 
with β-lactam-HSA adducts and synthetic designer peptides modified with β-lactam haptens 65 
(12,13). It is well-known that antigen dose plays a crucial role in the severity of the 66 
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hypersensitive phenotype (14,15) and in determining the characteristics of the responding T-67 
cell repertoire (16,17). Quantitative assessment of β-lactam hapten density on protein has 68 
been attempted previously (18,19); however, established  approaches lack sensitivity and are 69 
unable to accurately monitor the level of β-lactam adduct formed. The use of liquid 70 
chromatography coupled with mass spectrometry (LC-MS) together with suitable internal 71 
standards is now the most widely accepted technique for quantification purposes. Therefore, 72 
the purpose of this study was to develop and utilize mass spectrometric methods to quantify 73 
the level of β-lactam protein binding in tolerant and hypersensitive patients and to define the 74 
association between adduct exposure and the drug-specific T cell response. To address this 75 
objective, T-cell clones were generated using PBMC cultured with parent drug, which forms 76 
conjugates with multiple proteins in culture (4,20) and a synthetic conjugate using a single 77 
protein carrier (HSA). This allowed us to analyse T-cell receptor usage, chemokine receptor 78 
expression and cross-reactivity. The study focused on piperacillin, an intravenous β-lactam 79 
antibiotic often administered to patients with cystic fibrosis for the treatment of recurrent 80 
respiratory infections. Hypersensitivity reactions have been reported to develop in 81 
approximately 30% of patients exposed to multiple courses of the drug (21). Moreover, we 82 
have recently reported on (1) the profile of drug protein conjugation at specific lysine 83 
residues with respect to dose and incubation time, (2) the formation of two forms of drug 84 
hapten (with intact or hydrolysed 4-ethyl-2,3-dioxopiperazine ring; Figure 1A), and (3) the 85 
presence of piperacillin hapten-specific CD4+ T-cells in approximately 75% of 86 
hypersensitive patients (7,8). Thus, piperacillin represents the ideal candidate to investigate 87 
the quantitative relationship between adducts formed in the circulation of patients and that 88 
required to activate T-cells in vitro. 89 
 90 
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Materials and methods  92 
Patient details 93 
Plasma samples were isolated from blood of ten tolerant patients with cystic fibrosis prior to 94 
piperacillin exposure and immediately after a standard 14 day treatment course (4.5g qds) and 95 
three piperacillin hypersensitive patients at the time the reaction was diagnosed. Clinical 96 
characteristics of the patients are summarized in Table 1. Plasma was aliquoted stored at -97 
80
o
C immediately after isolation for characterization and quantification if piperacillin hapten 98 
HSA adducts.  99 
 100 
PBMC were also isolated from blood of 3 patients with historical delayed-onset piperacillin-101 
mediated hypersensitivity. The patients’ demographics, clinical features of reactions, skin 102 
testing and lymphocyte transformation test results are summarized in Table 2. Approval for 103 
the study was obtained from the Leeds local research ethics committee and informed written 104 
consent was received from participants prior to inclusion in the study. 105 
 106 
Detection of piperacillin-specific PBMC responses 107 
Proliferation of hypersensitive patients’ PBMC (0.15 X106 per well) against piperacillin 108 
(62.5–2000 µM) and tetanus toxoid (5 µg/ml; positive control) was measured using the 109 
lymphocyte transformation test (8). Proliferative responses were measured by the addition of 110 
[
3
H]thymidine for the final 16h of the assay. Cells were cultured in RPMI 1640 medium, 111 
containing 10% AB serum, 100mM L-glutamine, 25mM HEPES, and 25μg/ml transferrin. 112 
100μg/ml. 113 
 114 
Synthesis of piperacillin-modified peptides 115 
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Our previous studies showed that selective modification of Lys541 was observed at low 116 
piperacillin concentrations, whereas at higher concentrations up to 13 lysine residues were 117 
modified, four of which (Lys190, 195, 432 and 541) were detected in patients’ plasma. Thus, 118 
we developed a method to synthesize ATK(piperacillin)EQLK; an amino acid sequence 119 
incorporating Lys541 in HSA. Synthesis of the piperacillin-modified peptide was achieved by 120 
Fmoc chemistry in solution phase. Amino acid side chain protection was effected by the 121 
following: triphenilmethyl for glutamine; tert-butyl for aspartic acid, glutamic acid, and 122 
threonine; and benzyloxycarbonyl (Z) for C-terminus lysine. The synthesis was initiated with 123 
lys(Z)-OBn salt as shown in Figure 1. The coupling reactions were activated by means of 124 
addition of N,N'-dicyclohexylcarbodiimide, in the presence of 1-hydroxybenzotriazole and a 125 
base such as N-methylmorpholine. The Fmoc deprotection step was accomplished twice with 126 
20% piperidine in chloroform for 10 min. The efficiency of these reactions was evaluated by 127 
the ninhydrin colorimetric reaction. Once the synthesis was complete, the deprotection 128 
processes were carried out following a series of sequential steps: firstly, benzyl or Z groups 129 
were removed by catalytic transfer hydrogenation; secondly, Fmoc was removed with 50% 130 
diethylamine in acetonitrile; and finally, cold diethyl ether was added to precipitate the 131 
peptide. The crude peptide was purified by semi-preparative HPLC on a Jupiter C18 column 132 
(10μm C18, 250 mm × 10mm, Phenomenex, Macclesfield, Cheshire, U.K.) with a linear 133 
gradient of 95-50% solvent A (0.05% trifluoroacetic acid in water) in solvent B (0.05% 134 
trifluoroacetic acid in acetonitrile) over 30 min at a flow rate of 5mL/min.  The purity of 135 
peptide was determined by UV spectroscopy and the structure was characterised by MS/MS 136 
analysis. The 1H NMR spectra were recorded in CDCl3 or MeOD at 400 MHz on a Bruker 137 
Advance NMR spectrometer. 138 
 139 
 140 
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Isolation of HSA from plasma 141 
HSA was isolated by affinity chromatography. In brief, a POROS anti-HSA affinity cartridge 142 
(Applied Biosystems, Foster City, CA, USA) attached to a Vision Workstation (Applied 143 
Biosystems) was used to affinity capture HSA which was then eluted with 12 mM 144 
hydrochloric acid. Protein was methanol precipitated, and analysed by reversed phase LC-145 
MS. 146 
 147 
Mass spectrometric analysis of piperacillin-modified HSA 148 
Analyses were performed on a 5500 QTRAP® hybrid triple-quadrupole/linear ion trap 149 
instrument with Nanospray® II source (AB SCIEX, Foster City, CA, USA) and automated 150 
in-line liquid chromatography (U3000 HPLC system, 5 mm C18 nano-precolumn and 75 µm 151 
x 15 cm C18 PepMap column, Dionex) via a 10 µm inner diameter PicoTip emitter (New 152 
Objective). A gradient from 2% ACN/0.1% formic acid (v/v) to 50% ACN/0.1% formic acid 153 
(v/v) in 70 min was applied at a flow rate of 300 nL/min. The ionspray potential was set to 154 
2200-3500 V, the nebulizer gas to 18 and the interface heater to 150 
o
C. MRM transitions 155 
specific for drug modified peptides were selected as follows: the m/z values for all possible 156 
modified peptides with a missed cleavage at the modified lysine residue were used together 157 
with a fragment mass of 160 corresponding to the cleaved thiazolidine ring of the drug. MRM 158 
transitions were acquired at unit resolution in both the Q1 and Q3 quadrupoles to maximize 159 
specificity. They were optimized for collision energy and collision cell exit potential, and the 160 
dwell time was 50 ms. MRM survey scans were used to trigger enhanced product ion scans of 161 
piperacillin-modified peptides, with Q1 set to unit resolution, dynamic fill selected, and 162 
dynamic exclusion for 20 s. Notwithstanding the disparity in the ionisation efficiency of the 163 
peptides, relative MRM peak areas for each of the modified peptides were determined by 164 
MultiQuant software version 2.0 (AB SCIEX). The total ion count for the whole digest for 165 
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each sample was normalised to an internal synthetic peptide ATKEQLK that contains 166 
unmodified K541: in this way, the MRM signals were adjusted for differences in sample 167 
loading on-column. Relative quantification of modified peptides was performed by 168 
comparing the relative normalized MRM peak areas for each of the modified residues across 169 
samples. To achieve the absolute quantity of piperacillin modification formed in vitro, in cell 170 
culture medium, and in patients, synthetic piperacillin-modified peptide ATK(Pip)EQLK was 171 
spiked into tryptic HSA digests to construct calibration curves. Six calibration standards 172 
containing peptide ATK(pip)EQLK (30, 75, 150, 225, 375, 750 fmol) were prepared. The 173 
quantities of piperacillin modification in samples were calculated against calibration curve.  174 
 175 
Synthesis of drug-modified albumin conjugates 176 
Synthetic drug HSA conjugates were generated for functional studies by incubating drugs 177 
(piperacillin, penicillin G, and amoxicillin) with HSA at molar ratio of 2:1-250:1 for 24 h in 178 
phosphate buffer. The conjugates were purified by ultracentrifuge with a 3,000 MW cut off 179 
centrifugal filter (Amicon Ultra-15, Millipore, UK) according to the manufactory’s protocol. 180 
Briefly, 600 µL conjugates were added to the filter device followed by addition of 14 mL 181 
phosphate buffer (10mM, pH7.4). The device was centrifuged at 5000Xg for 20 min and the 182 
filtrate was discarded. The process of washing was repeated 6 times until the concentration of 183 
the free drug has been sufficiently reduced. The concentration of free drug in the filtrate from 184 
the last wash was determined by LC-MS and was found to be below 2.5nM. 185 
 186 
Generation of T-cell clones 187 
Antigen-specific T-cells were enriched by culturing PBMC with piperacillin or the 188 
piperacillin albumin adduct (generated using a molar ratio of 250:1 [drug:protein] for 24 h) 189 
for 14 days. IL-2 (60 U/ml) was added to maintain antigen specific proliferation. T-cells were 190 
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cloned by serial dilution using established methodology without purification of CD4+ or 191 
CD8+ T-cells (8). To test the specificity of the clones, T-cells (5 X 10
4
) were incubated with 192 
irradiated antigen-presenting cells (Epstein–Barr virus- transformed B-cell lines; 1 X 104) and 193 
piperacillin (2mM) or a piperacillin albumin adduct (2mg/ml) for 48 h. [
3
H]thymidine 194 
(0.5µCi) was added, and 16 h later proliferation was measured by scintillation counting. TCR 195 
Vβ protein expression was measured by flow cytometry using the IOTest Beta Mark TCR Vβ 196 
repertoire kit (Immunotech, Beckman Coulter, UK). Data was analysed using Cyflogic 197 
software (CyFlo Ltd., Finland). Cell phenotyping was performed using antibodies against 198 
CD4, CD8, CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR8, CCR9, CCR10, CXCR1, 199 
CXCR3, CXCR6 and CLA. 200 
 201 
Characterization of piperacillin-specific T-cell responses and quantification of 202 
piperacillin albumin binding 203 
The addition of piperacillin to cell culture medium results in modification of albumin, and a 204 
multitude of other proteins, that could act as antigenic determinants. To quantify the 205 
relationship between piperacillin protein binding in vitro and the activation of T-cells, drug-206 
responsive CD4+ clones were cultured with (1) antigen presenting cells and titrated 207 
concentrations of piperacillin (0.01-2mM) and (2) antigen presenting cells pulsed with 208 
titrated concentrations of piperacillin (0.1-2mM) for 1-48h. In the latter experiments, antigen 209 
presenting cells were washed with medium (3x5ml) and cultured with clones in the absence 210 
of free drug. Finally, antigen presenting cells were fixed with glutaraldehyde to block protein 211 
processing. Supernatant was collected from each experiment to quantify piperacillin HSA 212 
adducts. The proliferative response of the clones was measured by the addition of 213 
[
3
H]thymidine.   214 
 215 
Meng et al 10 
 
10 
 
Characterization of piperacillin albumin adduct-responsive T-cell clones and 216 
quantification of piperacillin albumin binding 217 
Experiments were also conducted using piperacillin albumin adducts to quantify the level of 218 
protein binding required to activate CD4+ T-cells. Importantly, these experiments used 219 
clones generated by culturing PBMC with a synthetic piperacillin-HSA conjugate. First, 220 
clones were incubated with antigen presenting cells and titrated concentrations of either 221 
soluble piperacillin or the piperacillin albumin adduct generated using a molar ratio of 250:1 222 
(drug:protein) for 24 h (0.25-2mg/ml). Unmodified albumin subjected to the same extraction 223 
protocol was used as a control. Second, clones were incubated with antigen presenting cells 224 
and piperacillin albumin adducts generated using molar ratios of 2:1-250:1 (drug:protein) for 225 
24 h (2mg/ml). Third, antigen presenting cells were fixed with glutaraldehyde to block 226 
protein processing and the generation of new MHC associated peptide antigens. Finally, 227 
crossreactivity was assessed by incubating clones with antigen presenting cells and 228 
piperacillin, penicillin G or amoxicillin albumin adducts generated using molar ratios of 229 
100:1-250:1 (drug:protein) for 24 h (2mg/ml). The proliferative response of the clones was 230 
measured by the addition of [
3
H]thymidine.  231 
 232 
Statistical analysis 233 
Multiple clones (up to 13 per experiment) were used to analyse T-cell responses. Experiments 234 
were conducted in duplicate or triplicate. Mean±SD was calculated, and statistical analysis 235 
was performed using paired T test (Sigmaplot 12 software).   236 
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Results 237 
Synthesis of piperacillin-modified albumin peptides 238 
To quantify drug hapten albumin binding a piperacillin-modified HSA peptide incorporating 239 
the amino acid sequence around Lys541 (ATK[Pip]EQLK) was synthesized using Fmoc 240 
chemistry (Figure 1A). The presence of a doubly charged ion at m/z 676.8 on the MS/MS 241 
spectrum (Figure 1B), corresponding to the peptide ATKEQLK with an additional mass of 242 
535 amu, demonstrated that a hydrolysed piperacillin-modified peptide was formed. The 243 
peptide sequence was confirmed by a product ion spectrum that generated partial singly 244 
charged y and b series ions. The modification was defined by b3* (peak at m/z 517) and b4* 245 
(peak at m/z 646), with addition of 216 amu, providing evidence that piperacillin is attached 246 
to K541 (Figure 1B). Purification of crude peptide products by HPLC afforded peptide 247 
ATK(piperacillin)EQLK in greater than 90% purity.  248 
 249 
Quantitative analysis of piperacillin-modified albumin in tolerant and hypersensitive 250 
patients 251 
In contrast to the two hapten structures detected on piperacillin albumin adducts generated in 252 
vitro (cyclised and hydrolysed; Figure 2A), the hydrolysed form was the only hapten detected 253 
on albumin Lys residues in tolerant patient plasma, with triptic peptides incorporating Lys541 254 
and Lys190 being the dominant sites of modification (results not shown). A total of four 255 
lysine residues, namely Lys190, Lys432, Lys 525, and Lys541, were detected in all patients 256 
(Figure 2B). A calibration curve was constructed using the synthetic piperacillin-Lys541 257 
peptide to quantify piperacillin albumin binding in tolerant patient plasma after a 14 day 258 
treatment course (Figure 2C); the analyses were conducted on three separate occasions. The 259 
level of modification of Lys541 in total HSA ranged from 2.7-4.7% (mean 3.86%); with 6 260 
patients displaying modification levels of 4% or more (Figure 2D).   261 
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 262 
The analysis was repeated with plasma from 3 patients that developed hypersensitivity 1, 6, 263 
and 10 days after commencement of piperacillin therapy. Piperacillin albumin adducts 264 
formed rapidly in patients, with 2% modification detected within 24 h (patient 032; Figure 2E 265 
& F). The level of modification in patients that developed hypersensitivity 6 and 10 days after 266 
treatment commenced matched those circulating in tolerant patients (Figure 2E & F).   267 
 268 
Generation of piperacillin-responsive T-cell clones and characterization of the minimal 269 
quantity of piperacillin hapten albumin binding required for T cell activation 270 
Seventy seven piperacillin-responsive clones were isolated from 3 LTT positive patients with 271 
a history of piperacillin-mediated maculopapular exanthema (Table 2). The majority of 272 
clones were CD4+; 4 clones expressed CD8, while 2 clones expressed CD4 and CD8 273 
receptors. Fifteen distinct Vβ T-cell receptors were detected on 53 out of 64 clones analysed. 274 
T-cell receptor Vβ 5.1, 13.1 and 17 were detected with the greatest frequency (Figure 3A). As 275 
described recently (22) clones expressed several chemokine receptors, including CCR4, 9 and 276 
10, and CXCR3 (Figure 3B). Soluble piperacillin, which forms conjugates with multiple 277 
proteins in culture medium, activated the clones in a concentration-dependent manner (0.5-278 
4mM; Figure 3C).   279 
 280 
Twenty CD4+ clones were used to study the relationship between piperacillin hapten protein 281 
binding and T-cell activation. Since these clones were not activated with synthetic 282 
piperacillin-HSA adducts, albumin was used as a surrogate protein to relate the level of 283 
piperacillin adduct formed to the activation of T-cells. First, the piperacillin concentration in 284 
the proliferation assay was reduced to establish a threshold for T-cell stimulation. A weak 285 
piperacillin-specific T-cell proliferative response was detected with 5/9 clones at a 286 
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concentration of 0.01mM (Figure 3 D & E). However, statistical significance was only 287 
reached with concentrations of 0.1mM and above (Figure 3D). Coinciding with the T-cell 288 
response at 0.1mM piperacillin, approximately 1% of piperacillin-modified K541 was 289 
detectable after 48h. Increasing the concentration of piperacillin resulted in higher levels of 290 
piperacillin hapten-modified Lys 541, with 4.7% modification detected at 2mM piperacillin. 291 
Moreover, piperacillin hapten albumin binding was detected at earlier time-points (4-24h) 292 
with piperacillin concentrations of ranging from 0.5-4mM (Figure 3F). As described 293 
previously, fixation of antigen presenting cells, which blocks protein processing (24-27), 294 
prevented the piperacillin-specific activation of all clones (results not shown).  295 
 296 
In contrast to our previous study using a piperacillin-albumin conjugate purified through 297 
solvent precipitation (free piperacillin concentration, 150nM) (7), clones were not activated 298 
with the albumin conjugate used herein (Figure 3G). As described above, free piperacillin 299 
was removed from the conjugate by repeated ultrafiltration and the non-covalently bound 300 
drug concentration was less than 2.5nM. 301 
 302 
The level of piperacillin hapten adduct required for triggering T-cells was determined by 303 
pulsing antigen presenting cells with piperacillin (2mM) for 1, 4, 24, and 48h prior to 304 
washing and exposure of the antigen presenting cells to clones. Antigen-presenting cells 305 
pulsed with piperacillin for 1 and 4 h did not stimulate a proliferative response and only low 306 
levels of piperacillin-modified Lys541 was detected (Figure 4). In contrast, 24 and 48h 307 
pulsed antigen presenting cells stimulated all clones to proliferate and the strength of the 308 
induced response was equivalent to or stronger than that seen with the soluble drug (Figure 309 
4). From this data it can be seen that 2.8% of Lys541 in HSA is modified by piperacillin 310 
when protein adducts are generated to activate T-cell proliferative responses. 311 
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 312 
Generation of piperacillin HSA adduct-responsive T-cell clones  313 
Since clones generated through the culture PBMC of with the parent compound are activated 314 
via a hapten mechanism with piperacillin protein adducts other than piperacillin-modified 315 
albumin, additional experiments were conducted to generate piperacillin-albumin conjugate-316 
responsive clones. A piperacillin HSA adduct generated by culturing piperacillin and HSA at 317 
a ratio of 250:1 for 24h, prior to purification by ultracentrifugation, was used to activate 318 
patient PBMC. After 2 weeks in culture, T-cells were cloned by serial dilution. 22 CD4+ and 319 
1 CD8+ clone were stimulated to proliferate with the piperacillin HSA adduct. As one would 320 
expect with the limited number of drug-modified peptide epitopes that can be generated from 321 
the piperacillin-albumin conjugate, the clones displayed a restricted pattern of Vβ receptor 322 
expression; Vβ 9 was expressed on 15 clones, while other clones expressed Vβs 2, 17 and 20 323 
(Figure 5A). Thirteen piperacillin HSA adduct-responsive clones were analysed for 324 
chemokine receptor expression. High expression of CCR2, 4, 8, 9, 10 and CXCR3 was 325 
detected (Figure 5B).  326 
 327 
Clones were stimulated to proliferate with titrated concentrations of the piperacillin HSA 328 
adduct (0.25-2mg/ml [Figure 5C]; concentrations of 0.1mg/ml and below did not activate 329 
clones) via a pathway dependent on protein processing (i.e., glutaraldehyde fixation of 330 
antigen presenting cells inhibited the antigen-specific proliferative response [results not 331 
shown]). Importantly, unmodified HSA processed in the same way as the piperacillin HSA 332 
adduct did not activate the clones (Figure 5D). Ten well-growing clones were expanded and 333 
used to determine the minimum level of piperacillin hapten binding required to activate T-334 
cells. Piperacillin HSA adducts generated at drug:HSA ratios of 10:1 – 250:1 were found to 335 
stimulate the clones to proliferate (Figure 5E), with the strength of the response increasing 336 
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with increasing levels of piperacillin hapten modification. Although piperacillin-HSA adducts 337 
are generated spontaneously in cell culture medium containing free drug, only 50% of the 338 
clones were activated with soluble drug, and the strength of the proliferative response was 339 
significantly weaker (Figures 5F & G). Despite this, the concentration of piperacillin required 340 
to activate the clones and the kinetics for T-cell activation (i.e., the antigen presenting cell 341 
pulse duration) were the same as described with clones depicted in figures 3 and 4.  342 
 343 
The synthetic piperacillin-HSA conjugates were characterised by mass spectrometry and 344 
western blot. Epitope profiling showed that both cyclised and hydrolysed hapten were 345 
formed; piperacillin-modified K541 was the major site of binding (Figure 5H & I). The levels 346 
of hydrolysed piperacillin-modified K541 increased with higher concentrations of 347 
piperacillin, ranging from 3.6% at the lowest T-cell stimulatory concentration to 23.5% at a 348 
drug:protein ratio of 250:1 (Figure 5J). The concentration-dependent binding of piperacillin 349 
was also mirrored using western blotting (Figure 5K). 350 
 351 
Piperacillin HSA adduct-responsive T-cell clones are not activated with other β-lactam 352 
HSA adducts 353 
Penicillin G, amoxicillin and piperacillin HSA adducts were generated by culturing the drugs 354 
with HSA at 100:1 and 250:1 ratios for 24h. Epitope profiles showed that the same subset of 355 
Lys residues was targeted by all three drugs; however, the relative level of binding differed at 356 
the individual sites of modification (Figure 6A & B). Piperacillin HSA adduct-responsive 357 
clones were not stimulated to proliferate with either penicillin G or amoxicillin HSA adducts 358 
(Figure 6C & D).  359 
  360 
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Discussion 361 
It is currently impossible design drugs with no immunological liability; furthermore, it is very 362 
difficult to predict which individuals will develop hypersensitivity when exposed to a 363 
therapeutic treatment regimen. One of the predominant problems is the complexity of 364 
processes that deliver drug-derived antigens to the T-cell receptor. In vitro analyses have 365 
revealed that certain drugs bind directly to the MHC peptide binding cleft and/or pre-bound 366 
peptides to activate T-cells (26-31). However, the dominant pathway for drugs such as the β-367 
lactam antibiotics (23,26,32-34) and sulphonamides (35-37) involves the formation of a 368 
protein adduct with the drug hapten bound irreversibly to specific amino acid residues on 369 
non-MHC associated protein. The protein adduct is processed by antigen presenting cells 370 
liberating peptides that associate with MHC molecules to activate T-cells.   371 
 372 
Our previous studies have demonstrated that the β-lactam antibiotic piperacillin covalently 373 
modifies Lys residues at drug binding “Sudlow sites” on HSA in plasma (8). Moreover, 374 
piperacillin stimulates hypersensitive patient circulating and skin resident T-cells to 375 
proliferate and secrete effector molecules, including the tissue-specific cytokine IL-22 (7,22). 376 
El-Ghaiesh et al (7) found that all piperacillin-responsive clones were activated with a 377 
piperacillin HSA adduct containing 150nM piperacillin bound non-covalently to the protein. 378 
We repeated these experiments and found comparable results (data not shown). However, in 379 
the present study using a fully characterised, and highly purified  HSA adduct, for which we 380 
have used low molecular weight mass spectrometry to exclude the presence of non-381 
covalently-associated piperacillin above an analytical limit of 2.5nM, we can now rigorously 382 
demonstrate two classes of clones from the same patient: firstly, clones stimulated by a single 383 
protein (albumin) adduct per se; and secondly, clones stimulated as a result of modification 384 
of proteins present in the incubation by addition of the parent drug. CD4+ T-cells expressing 385 
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skin homing receptors such as CCR4 and CCR10 were selectively activated with either the 386 
piperacillin albumin adduct or the parent drug, via a hapten mechanism. All clones were 387 
activated with piperacillin-pulsed antigen presenting cells. Furthermore, fixation of antigen 388 
presenting cells, which blocks protein processing, inhibited the activation of T-cells with 389 
piperacillin. Thus, we did not identify clones that were activated with the parent drug bound 390 
directly to MHC via a P-I mechanism. The piperacillin albumin adduct-responsive clones 391 
displayed a more restricted profile of Vβ receptors, which may relate to the limited number of 392 
epitopes available for MHC T-cell receptor binding (approximately 10-12), when compared 393 
with the parent drug, which in theory could modify 1000s of serum and/or cellular proteins 394 
within the culture medium. Analysis of piperacillin hapten binding in patient’s plasma and in 395 
vitro revealed that piperacillin binds to HSA within 24 h at comparable levels. Thus, 396 
antigenic determinants with the potential to activate T-cells and cause tissue injury are 397 
formed in all patients exposed to the drug.  398 
 399 
The availability of piperacillin hapten-specific clones with specificity for albumin adducts 400 
lead us to investigate whether the level of piperacillin HSA modification differs in tolerant 401 
and hypersensitive individuals exposed to the same treatment regimen. To do this, a synthetic 402 
drug hapten peptide standard incorporating amino acid residues found in the native protein 403 
(38,39) was generated. 3.9% of Lys 541 in HSA isolated from plasma of tolerant patients 404 
exposed to piperacillin for 14 days was modified with the piperacillin hapten. The level of 405 
Lys541 binding ranged from 2.7-4.7%, indicating that there is a 2 fold difference in exposure 406 
to piperacillin HSA adducts in patients exposed to the same treatment regimen. Somewhat 407 
surprisingly, the piperacillin hapten with a hydrolysed 4-ethyl-2,3-dioxopiperazine ring was 408 
the only moiety bound to HSA in patient plasma, which indicates that this form of the hapten 409 
almost certainly interacts with T-cell receptors expressed on antigen-specific T-cells.  410 
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 411 
The level of Lys541 modification on albumin from patients sampled on the day of 412 
hypersensitivity diagnosis (days 1, 6 and 10) matched those circulating in tolerant patients, 413 
which indicates that the level of covalent binding in all patients exposed to piperacillin is 414 
sufficient to activate T-cells; however, only a portion of patients develop hypersensitivity. 415 
Thus, the propensity to develop hypersensitivity may be dependent on the presence of T-cells 416 
within an individual’s repertoire that can be activated with the β-lactam hapten and/or an 417 
imbalance in immune regulation. Interestingly, piperacillin albumin adducts were formed 418 
rapidly after commencement of piperacillin therapy. After day 1 of treatment, the level of 419 
Lys541 modification exceeded 2%.  420 
 421 
These data quantifying piperacillin protein adducts in plasma led us to measure the threshold 422 
level of HSA modification using piperacillin concentrations required to activate T-cells. 423 
CD4+ T-cell clones were cultured with antigen presenting cells and titrated concentrations of 424 
piperacillin to ascertain the lowest drug concentration associated with a significant 425 
proliferative response. Piperacillin-modified K541 was detectable at 0.1mM, the lowest 426 
concentration associated with T-cell proliferative responses. A dose-dependent increase in the 427 
level of modification was observed with piperacillin concentrations associated with a 20-fold 428 
increase in the proliferation of T-cells (i.e., 0.5-4mM). Importantly, equivalent levels of 429 
Lys541 modification were detected in patient plasma and in vitro with piperacillin 430 
concentrations that stimulated a T-cell response. To estimate the absolute levels of HSA 431 
binding at the earliest possible time that T-cells are activated, antigen-presenting cells were 432 
pulsed with piperacillin (2mM) for 1-48h prior to washing and exposure of clones to the 433 
pulsed cells. Antigen presenting cells pulsed with piperacillin for 24h stimulated all clones to 434 
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proliferate and the strength of the response was stronger to that seen with the soluble drug. At 435 
this time-point 2.8% of Lys541 was modified with the piperacillin hapten.  436 
 437 
Since T-cell clones cultured with soluble piperacillin are activated by the drug hapten bound 438 
covalently to protein carriers other than HSA, a synthetic β-lactam HSA adduct was 439 
generated to (1) assess the relationship between the level of hapten binding and the T-cell 440 
response and (2) study T-cell reactivity with other β-lactam protein adducts. Piperacillin HSA 441 
adducts were generated with 3.6-23.5% Lys541 modification by culturing piperacillin with 442 
HSA at ratios of 10:1-250:1. The response of all piperacillin HSA adduct-responsive clones 443 
was blocked by gluturaldehyde fixation indicating that the clones were activated via a hapten 444 
mechanism involving the generation of antigenic HSA-derived peptides. Furthermore, the 445 
response was restricted to the piperacillin hapten structure as other β-lactam HSA adducts did 446 
not activate the T-cells. In line with our previous findings, the preference of β-lactam 447 
antibiotics for different lysine residues in albumin is driven at least in part by the initial non-448 
covalent interaction, which positions the drug in a favourable position to facilitate covalent 449 
binding. The three-dimensional shape of the drug as well as its inherent chemical reactivity 450 
therefore determines selectivity of covalent binding and as demonstrated in figure 6 the 451 
activation of T-cells. An increase in the level of piperacillin modification at Lys541 452 
correlated with the strength of the T-cell proliferative response (r
2
=0.96). Clones were 453 
initially activated with an adduct generated at a drug:protein ratio of 10:1; quantitative mass 454 
spectrometry revealed that 3.6% of Lys541 was modified with the piperacillin hapten. 455 
 456 
Collectively, our data reveal that the level of drug hapten protein binding in tolerant and 457 
hypersensitive patients exposed to a therapeutic treatment regimen is sufficient to activate T-458 
cells. Thus, it is important that future research focuses on why most patients do not develop a 459 
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drug antigen-specific T-cell response and clinical manifestations of hypersensitivity.  To do 460 
this, we have recently initiated a prospective investigation of piperacillin hypersensitivity. 461 
Bloods samples are being collected during repeated drug courses and when patients develop 462 
an adverse event to define the quantitative relationship between antigen formation and the 463 
factors that control the balance between immune tolerance and activation.  464 
 465 
  466 
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Figure legends 619 
Figure 1. Synthesis of a piperacillin-modified peptide incorporating Lys541. (A) Scheme 620 
showing the synthetic pathway for piperacillin modified K541 peptide ATK(Pip)EQLK. (B) 621 
MS/MS spectra of synthetic peptide ATK(Pip)EQLK with characteristic  fragment ions from 622 
piperacillin circled. 623 
 624 
Figure 2. Piperacillin hapten structures and absolute quantification of piperacillin 625 
hapten albumin binding in tolerant and hypersensitive patient plasma. (A) Scheme 626 
showing the 2 potential piperacillin haptens bound covalently to protein. (B) Model of 627 
albumin showing piperacillin lysine binding sites in patients. (C) Standard curve constructed 628 
using synthetic piperacillin-modified K541 peptide with concentrations ranging from 0.05µM 629 
to 1.5µM. (D, E) Absolute level of piperacillin-modified K541 peptide detected in plasma 630 
from (D) tolerant and (E) hypersensitive patients. Mass spectrometric analysis was repeated 631 
on 3 separate occasions. (F) Comparison of piperacillin K541 binding in hypersensitive (   ) 632 
and tolerant (   ) patients showing day of analysis.  633 
 634 
Figure 3. Processing-dependent activation of piperacillin-responsive CD4+ clones from 635 
hypersensitive patients and quantification of piperacillin albumin binding. (A, B) Flow 636 
cytometric analysis of (A) T-cell receptor Vβ and (B) chemokine receptor expression on 637 
pipercillin-responsive clones. (C, D) T-cell clones were cultured with irradiated antigen 638 
presenting cells and piperacillin ([C] 0.5-4mM; [D] 0.01-100µM) and proliferative responses 639 
were measured by [
3
H]thymidine uptake. (E) Representative proliferative response of 2 640 
clones shown in D. (F) The absolute level of time-dependent piperacillin-modified K541 641 
peptide detected in culture supernatant. (G) T-cell clones were cultured with irradiated 642 
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antigen presenting cells and piperacillin or HSA adducts and proliferative responses were 643 
measured by [
3
H]thymidine uptake.  644 
 645 
Figure 4. Time-dependent activation of CD4+ clones with piperacillin-pulsed antigen 646 
presenting cells and quantification of piperacillin albumin binding. (A) T-cell clones 647 
(n=8) were cultured with antigen presenting cells pulsed with piperacillin (2mM; 1-48h) and 648 
proliferative responses were measured by [
3
H]thymidine uptake. Antigen presenting cells 649 
were subjected to repeated washing with drug-free medium prior to exposure to clones. (B) 650 
The absolute level of time-dependent piperacillin-modified K541 peptide detected in antigen 651 
presenting cell culture supernatant. 652 
 653 
Figure 5. Processing-dependent activation of piperacillin-modified albumin responsive 654 
CD4+ clones from hypersensitive patients and quantification of piperacillin albumin 655 
binding. (A, B) Flow cytometric analysis of (A) T-cell receptor Vβ and (B) chemokine 656 
receptor expression on pipercillin-responsive clones. (C) T-cell clones were cultured with 657 
irradiated antigen presenting cells and piperacillin-modified HSA (generated using a molar 658 
ratio of 250:1 drug:protein for 24h) and proliferative responses were measured by 659 
[
3
H]thymidine uptake. (D) Proliferative response of T-cell clones cultured with unmodified 660 
and piperacillin-modified HSA and antigen presenting cells. (E) Proliferative response of T-661 
cell clones cultured with antigen presenting cells and piperacillin-modified HSA adducts 662 
generated using different molar ratios of drug:protein. (F, G) Proliferative response of T-cell 663 
clones cultured with antigen presenting cells and piperacillin-modified HSA adducts or 664 
piperacillin ([F] combined data; [G] representative clones]. (H, I) Relative quantification of 665 
(H) cyclysed and (I) hydrolysed forms of the piperacillin hapten generated at different lysine 666 
residues on the piperacillin albumin adduct (drug:protein ratios of 10:1-250:1). (J) The 667 
Meng et al 31 
 
31 
 
absolute level of piperacillin-modified K541 peptide detected on the piperacillin albumin 668 
adductd generated at drug:protein ratios of 10:1-250:1. (K) Western blot analysis of the 669 
piperacillin albumin adducts. 670 
 671 
Figure 6. Piperacillin-albumin adduct-responsive CD4+ clones are not activated with 672 
alternative β-lactam albumin adducts. (A,B) Relative mass spectrometric quantification of 673 
Benzyl penicillin, amoxicillin and piperacillin haptens formed at different lysine residues in 674 
vitro when the drug was incubated at drug:protein ratios of (A) 100:1 and (B) 250:1. (C,D) T-675 
cell clones (n=5) were cultured with irradiated antigen presenting cells and benzyl penicillin, 676 
amoxicillin, or piperacillin-modified HSA (generated using a molar ratio of (C) 100:1 or (D) 677 
250:1 drug:protein for 24h) and proliferative responses were measured by [
3
H]thymidine 678 
uptake. 679 
 680 
  681 
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Table 1. Clinical characteristics of the drug tolerant and hypersensitive patients used in the mass spectrometric analyses  
 
F: female; M: male; MPE: maculopapular exanthema; NT: not tested; ID: intradermal; LTT: lymphocyte transformation test. 
+: SI 2-5; ++: SI 5-10; +++: SI 10-20; ++++: >20 
a
 Days after commencement of therapy that plasma HSA was analyzed by mass spectrometry for piperacillin covalent binding.  
 
 
Patient 
ID 
Drug Reaction Clinical features Time to reaction 
(days) 
Day of analysis
a 
(days) 
No. of courses 
prior to reaction
 
Hypersensitive patients 
032 
Tazocin Maculopapular rash 
Age 33, Male; df508/df508; Chronic 
Pseudomonas Infection; FEV1 2.27 litres (57% 
predicted); Pancreatic insufficient; CF related 
diabetes mellitus 
1 1 8 
040 
Tazocin Facial rash, pruritis 
Age 20, Female;  df508/df508; Chronic 
Pseudomonas infection; FEV1 0.43 litres (15% 
predicted); Pancreatic insufficient; CF related 
diabetes mellitus 
6 6 6 
059 
Tazocin Maculopapular rash 
Age 26, Female; df508/unknown; Chronic 
Pseudomonas infection; FEV1 1.84 litres 
(54%); Pancreatic insufficient 
10 10 8 
Tolerant patients 
006 Tazocin -  - 14 n/a 
016 Piperacillin -  - 14 n/a 
020 Piperacillin -  - 14 n/a 
030 Tazocin -  - 14 n/a 
026 Tazocin -  - 14 n/a 
022 Tazocin -  - 14 n/a 
009 Tazocin -  - 14 n/a 
017 Tazocin -  - 14 n/a 
029 Tazocin -  - 14 n/a 
025 Tazocin -  - 14 n/a 
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Table 2. Clinical characteristics of the hypersensitive patients used in the immunological studies  
 
F: female; M: male; MPE: maculopapular exanthema; LTT: lymphocyte transformation test. 
+: SI 2-5; ++: SI 5-10; +++: SI 10-20; ++++: >20 
 
 
Patient 
ID 
Age 
(years) / 
Gender 
Clinical features Drug Reaction 
Delay between 
course 
initiation and  
reaction (days) 
Time since 
reaction 
(years) 
Delayed 
intradermal 
readings 
Piperacillin 
LTT 
A 26/M 
Chronic Pseudomonas infection; 
FEV1 2.87 litres (68% predicted); 
BMI 23; CF related diabetes; 5 
days of intravenous antibiotics 
over last 12 months 
Piperacillin 
Aztreonam 
Ceftazidime 
Meropenem 
MPE/Fevers 
MPE 
Delayed Angioedema 
MPE 
9 
4 
3 
5 
12 
10 
10 
10 
- 
- 
- 
- 
++ 
B 28/M 
Chronic Pseudomonas infection; 
FEV1 0.61lites (15% predicted); 
BMI 16; Osteoporosis; 197 days 
of intravenous antibiotics over 
past 12 months 
Piperacillin MPE 11 9 
+ve at 24 
hours 
+++ 
C 27/M 
Chronic Pseudomonas infection; 
FEV1 1.1lites (28% predicted); 
BMI 17; Osteoporosis; 96 days 
intravenous antibiotics over past 
12 months 
Ceftazidime 
Piperacillin 
MPE 
MPE/fever 
5 
2 
9 
5 
- 
+ve at 48 
hours 
++++ 
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